NCT04193527 - A Study to Evaluate the Diagnostic Efficacy of DaTSCAN™ Ioflupane (123I) Injection in Single Photon Emission Computed Tomography (SPECT) for the Diagnosis of Parkinsonian Syndrome (PS) in Chinese Patients | Biotech Hunter

Enrollment

172

Participants

Timeline

Start Date

June 28, 2020

Primary Completion Date

December 20, 2021

Study Completion Date

December 20, 2021

Conditions

Parkinsonian SyndromeParkinson Disease(PD)Multiple System Atrophy (MSA)Progressive Supranuclear Palsy (PSP)Essential Tremor

Interventions

DRUG

DaTSCAN™ Ioflupane (123I) Injection

All participants (Participants with PS, ET, and HV) received a single dose of DaTSCAN™ ioflupane (123I) injection within the range of 111 to 185 megabecquerel (MBq) (3 to 5 millicurie \[mCi\]) per participant at a maximum volume of 5 milliliter \[mL\]) intravenously on Day 1.

Trial Locations (10)

100029

Beijing Anzhen Hospital, Capital Medical University, Beijing

100034

Peking University First Hospital, Beijing

100050

Beijing Friendship Hospital Afflication to Capital Medical University, Beijing

100730

Peking Union Medical College Hospital, Beijing

200025

Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai

200080

Shanghai General Hospital, Hongkou

215004

The Second Affilicated Hospital of Soochow University, Suzhou

300052

Tianjin Medical University General Hospital, Tianjin

2100029

Nanjing First Hospital, Nanjing

Unknown

Nanfang Hospital, Nanfang Medical Univeristy, Guangdong